DOCK1 and liver cancer: Finally, we sought to determine whether DOCK1 expression levels could serve as a potential biomarker for evaluating the therapeutic effectiveness of metformin in liver cancer patients by retrospective evaluation of 122 clinical HCC patients with diabetes.